Inactive Instrument

Nanomix Corporation

NNMX

US63008H2013

Advanced Medical Equipment & Technology

Nanomix Names Tadd S. Lazarus to Board of Directors

Published on 08/31/2022 at 09:05 am EDT

S&P Capital IQ

NANOMIX CORPORATION

-.--%

Nanomix Names Tadd S. Lazarus to Board of Directors.

Latest news about Nanomix Corporation

23-11-24	Nanomix Corporation Announces Chief Executive Officer Changes	CI
23-04-07	Nanomix Corporation Reports Earnings Results for the Full Year Ended December 31, 2022	CI
23-04-06	Nanomix Corporation Auditor Raises 'Going Concern' Doubt	CI
23-01-25	Nanomix Corporation Appoints Christopher R. Hetterly as Chief Financial Officer	CI
22-11-29	Nanomix Corporation Enters into Distribution Agreement for the eLab System with Gepa Srl in Italy	CI
22-11-14	Nanomix Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	CI
22-11-09	Nanomix Corporation Enters into an Exclusive Veterinary Distribution Agreement for the eLab System with Woodley Equipment Company, Ltd	CI
22-11-08	Nanomix Corporation announced that it has received $0.069779 million in funding from Woodley Equipment Company Ltd.	CI
22-11-04	Nanomix Corporation Enters into Multi-Country Distribution Agreement for the Elab System with Mast Group Limited	CI
22-10-20	Nanomix Corporation Announces Distribution Agreement with Diaclinic SpA	CI
22-09-12	Nanomix Enters into Distribution Agreement for the Elab System and Future New Products with Ips Genomix S.A.L. in the Middle East	CI
22-09-02	Nanomix Corporation Announces Agreement with Mobility Health to Co-Develop a Lab Development Test for Evaluating Levels of COVID-19 Circulating Antibodies	CI
22-08-31	Nanomix Names Tadd S. Lazarus to Board of Directors	CI
22-08-31	Nanomix Corporation Appoints Tadd S. Lazarus to its Board of Directors as Independent Director	CI
22-08-23	Nanomix Enters into Distribution Agreement for the Elab System and Future New Products with Bioasia Pte Ltd in Singapore	CI

Nanomix Corporation is engaged in development of mobile point-of-care diagnostics. The Company operates through its Nanomix eLab System platform and assays that provide quantitative information for use in settings where time is critical to clinical decision-making and improved patient care. The platform is designed to provide rapid test results in a handheld device at the first point of patient contact in locations that range from emergency departments to long term and assisted care facilities, to urgent care and emergency medical response settings. Its platform is performed in a range of in vitro diagnostic assays, such as electrochemical immunoassay and enzymatic assays. Its eLab System utilizes a nano-biosensor with multiple detection electrodes to generate multiple electrochemical assay results. Its S1 Assay panel is used as an aid in diagnosing infections, such as sepsis. Its CRP test results can be used to evaluate infection, tissue injury, and inflammatory disorders.

Employees

Sector

Advanced Medical Equipment & Technology

More about the company